Featured Trial:
Head and Neck Cancer Treatment

Featured Trial:
Breast Cancer Treatment

Featured Trial:
Melanoma Prevention Study

Featured Trial:
Breast Cancer Recurrence

Featured Trial:
Bladder Cancer Treatment

Featured Trial:
Pancreas Cancer Treatment

Featured Trial:
Stomach Cancer Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

July 15, 2026

Categories

Press Releases

Press Release: ECOG-ACRIN ENDURANCE trial findings published in the New England Journal of Medicine provide the first randomized evidence on the optimal duration of lenalidomide maintenance for patients with newly diagnosed multiple myeloma

July 9, 2026

Categories

News Stories

Podcast: ASCO Post includes updated STAMP (EA6174) Merkel cell carcinoma data in its ASCO26 highlights, applauding cooperative groups for their ability to study rare cancers

June 29, 2026

Categories

The June 2026 News from ECOG-ACRIN blog is now available

June 10, 2026

Categories

Press Releases

Press Release: Elsa Anagnostou, Jordan Berlin, and Olisaemeka Ogbue receive ECOG-ACRIN 2026 scientific leadership and mentorship awards

June 4, 2026

Categories

News Stories

A new exploratory analysis from STAMP (EA6174) on aggressive Merkel cell cancer draws attention at ASCO 2026

June 2, 2026

Categories

News Stories

EA5142, an ALCHEMIST trial, adds to the knowledge base about optimal timing of adjuvant immunotherapy in non-small cell lung cancer

June 2, 2026

Categories

News Stories

WATCH: Dr. Jamie Chaft discusses the results of ALCHEMIST EA5142, a randomized phase 3 study of nivolumab after surgery and adjuvant chemotherapy in non-small cell lung cancer

June 1, 2026

Categories

News Stories

JAMA publishes ALCHEMIST EA5142 results: Nivolumab does not further reduce the risk of recurrence in patients with resected non-small cell lung cancer

May 28, 2026

Categories

The May 2026 News from ECOG-ACRIN blog is now available

Posts

ECOG-ACRIN Cancer Research Group Follow 9,315 6,577

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

23h 2077844773071675481

New @JCO_ASCO Podcast on Virtual Tobacco Treatment for Cancer Patients: @PsycholERPark & Jamie Ostroff discuss the groundbreaking EAQ171CD trial that’s bringing effective cessation support to community settings.

Listen now: https://bit.ly/VirTobEA
#TobaccoTreatment #CancerCare

Reply on Twitter 2077844773071675481 Retweet on Twitter 2077844773071675481 1 Like on Twitter 2077844773071675481 1 Twitter 2077844773071675481

Retweet on Twitter ECOG-ACRIN Cancer Research Group Retweeted

Elyse Park @PsycholERPark ·

14 Jul 2076848264494649703

Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program [July 13, 2026] @PsycholERPark et al. @JCO_ASCO
#NCORP @eaonc

Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial...

PURPOSEPersistent smoking among patients diagnosed with cancer is associated with adverse clinical outcomes, yet tobacco ...

ascopubs.org

Reply on Twitter 2076848264494649703 Retweet on Twitter 2076848264494649703 4 Like on Twitter 2076848264494649703 4 Twitter 2076848264494649703

Retweet on Twitter ECOG-ACRIN Cancer Research Group Retweeted

The ASCO Post @ASCOPost ·

15 Jul 2077506290171986307

🩸 Could 2 years of maintenance be enough for newly diagnosed #multiplemyeloma?

Phase III ENDURANCE trial found no OS benefit with indefinite lenalidomide vs stopping at 2 years, but higher toxicity with continuous therapy.

🔹 @myelomaMD | @NEJM

🔗 https://ascopost.com/news/july-2026/endurance-trial-in-newly-diagnosed-myeloma-no-survival-benefit-with-indefinite-maintenance-treatment-vs-2-years/

Reply on Twitter 2077506290171986307 Retweet on Twitter 2077506290171986307 3 Like on Twitter 2077506290171986307 2 Twitter 2077506290171986307

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).